Furthermore, repurposed candidates had a better approval rate, with 25% progressing from Phase II to approval, compared to only 10% of new drugs [14].Using an in-silico approach, this study aimed to find novel MCL-1 inhibitor to fight the BC. This evidence concerns the gene MCL1 and breast cancer.